Abstract
The lead optimization paradigm includes a team of experts that has a multitude of parameters to consider when moving from an initial lead compound through the lead optimization phase to the development phase. While in the past the team may have had only a medicinal chemist and a pharmacologist, the current team would often include experts in the areas of drug metabolism and pharmacokinetics (DMPK) as well as chemical toxicity. This review provides an overview of the some of the recent advances in the areas of DMPK screening plus a discussion of some of the assays that can be used to begin to screen for toxicity issues. The focus of this review is the major potential problem areas: oral bioavailability, half-life, drug-drug interactions and metabolism and toxicity issues.
Keywords: Drug metabolism, toxicology, lead optimization, drug discovery, oral bioavailability, half-life, ADME
Mini-Reviews in Medicinal Chemistry
Title: Advances in the Integration of Drug Metabolism into the Lead Optimization Paradigm
Volume: 9 Issue: 6
Author(s): Walter A. Korfmacher
Affiliation:
Keywords: Drug metabolism, toxicology, lead optimization, drug discovery, oral bioavailability, half-life, ADME
Abstract: The lead optimization paradigm includes a team of experts that has a multitude of parameters to consider when moving from an initial lead compound through the lead optimization phase to the development phase. While in the past the team may have had only a medicinal chemist and a pharmacologist, the current team would often include experts in the areas of drug metabolism and pharmacokinetics (DMPK) as well as chemical toxicity. This review provides an overview of the some of the recent advances in the areas of DMPK screening plus a discussion of some of the assays that can be used to begin to screen for toxicity issues. The focus of this review is the major potential problem areas: oral bioavailability, half-life, drug-drug interactions and metabolism and toxicity issues.
Export Options
About this article
Cite this article as:
Korfmacher A. Walter, Advances in the Integration of Drug Metabolism into the Lead Optimization Paradigm, Mini-Reviews in Medicinal Chemistry 2009; 9 (6) . https://dx.doi.org/10.2174/138955709788452694
DOI https://dx.doi.org/10.2174/138955709788452694 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Development of Oridonin Derivatives with Diverse Pharmacological Activities
Mini-Reviews in Medicinal Chemistry Novel and Emerging Drugs for Rarer Chronic Lymphoid Leukaemias
Current Cancer Drug Targets CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Signaling Pathways Modulating Dependence of Lung Cancer on Mutant Epidermal Growth Factor Receptor and Mechanisms of Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors
Current Pharmaceutical Design Therapeutic Perspectives for cN-II in Cancer.
Current Medicinal Chemistry Gene Therapy (Part II)
Current Gene Therapy In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia
Recent Patents on Anti-Cancer Drug Discovery miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets GSK-3 Inhibitors: Discoveries and Developments
Current Medicinal Chemistry New Opportunities to Treat the T315I-Bcr-Abl Mutant in Chronic Myeloid Leukaemia: Tyrosine Kinase Inhibitors and Molecules that Act by Alternative Mechanisms
Current Medicinal Chemistry Neuroprotective Role of Natural Polyphenols
Current Topics in Medicinal Chemistry Regulation of the Urokinase Receptor (uPAR) by LDL Receptor-related Protein-1 (LRP1)
Current Pharmaceutical Design The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies
Current Pharmaceutical Design Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers
Current Pharmaceutical Design Chemical Origins of Isoform Selectivity in Histone Deacetylase Inhibitors
Current Pharmaceutical Design The Use of L-Glucose in Cancer Diagnosis: Results from In Vitro and In Vivo Studies
Current Medicinal Chemistry Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy A Better Platinum-Based Anticancer Drug Yet to Come?
Anti-Cancer Agents in Medicinal Chemistry The Role of 3D Pharmacophore Mapping Based Virtual Screening for Identification of Novel Anticancer Agents: An Overview
Current Topics in Medicinal Chemistry